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Objective: To assess perioperative mortality following resection of biliary tract cancer within the U.S.
Background: Resection remains the only curative treatment for biliary tract cancer. However, current
data on operative mortality after surgical resections for biliary tract cancer are limited to small and
single-center studies.
Methods: Using the Nationwide Inpatient Sample 1998–2006, a cohort of patient-discharges was
assembled with a diagnosis of biliary tract cancer, including intrahepatic bile duct, extrahepatic bile duct,
and gall bladder cancers. Patients undergoing resection, including hepatic resection, bile duct resection,
pancreaticoduodenectomy, and cholecystectomy, were retained. The primary outcome measure was
in-hospital mortality. Categorical variables were analyzed by chi-square. Multivariable logistic regression
was performed to identify independent predictors of in-hospital mortality following resection.
Results: 31 870 patient-discharges occurred for the diagnosis of biliary tract cancer, including 36.2%
intrahepatic ductal, 26.7% extrahepatic ductal, and 31.1% gall bladder. Of the total, 18.6% underwent
resection: mean age was 69.3 years (median 70.0); 60.8% were female; 73.7% were white. Overall
inpatient surgical mortality was 5.6%. Independently predictive factors of mortality included patient age
50 (vs. <50; age 50–59 odds ratio [OR] 5.51, 95% confidence interval [CI] 1.70–17.93; age 60–69 OR
7.25, 95% CI 2.29–22.96; age  70 OR 9.03, 95% CI 2.86–28.56), the presence of identified comorbi-
dities (congestive heart failure, OR 3.67, 95% CI 2.61–5.16; renal failure, OR 4.72, 95% CI 2.97–7.49),
and admission designated as emergent (vs. elective; OR 1.82, 95% CI 1.39–2.37).
Conclusion: Increased in-hospital mortality for patients undergoing biliary tract cancer resection
corresponded to age, comorbidity, hospital volume, and emergent admission. Further study is warranted
to utilize these observations in promoting early detection, diagnosis, and elective resection.
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Introduction
After hepatocellular cancer, cholangiocarcinoma is the second
most common hepatobiliary malignancy.1 The incidence of the
different types of cholangiocarcinoma has shifted since 1975, with
an increase in intrahepatic cholangiocarcinoma and a slight
decrease in extrahepatic cholangiocarcinoma, possibly as a result
of an increase in chronic liver disease, hepatitis C and primary
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sclerosing cholangitis.2 Medical therapy is not effective; resection
provides the only cure.3,4
Multiple single-centre studies have examined outcomes of sur-
gical treatment of biliary tract cancer. Most have been small ret-
rospective studies given the low prevalence of the disease, and
have demonstrated that a minority of patients with gall bladder
and ductal cancer have resectable disease, and that curative resec-
tion is associated with the best survival benefit.5–7 The major goal
of this study was to examine factors associated with in-hospital
mortality for biliary tract cancers using a large, population-based
database. The Nationwide Inpatient Sample (NIS) was used to
determine the effect of covariates on mortality.
Methods and materials
A retrospective, population-based analysis was performed using
discharge records from the Nationwide Inpatient Sample (NIS)
for the years 1998–2006. The NIS is the largest national all-payer
hospital inpatient care database in the United States. Data exists
for nearly 8 million hospital discharges per year from a stratified
sample of 20% of non-federal US hospitals from participating
states, including academic hospitals.
The NIS is supported by the Healthcare Cost and Utilization
Project (HCUP) and contains all-payer discharge information
for 100% of patient discharges from 1045 hospitals in 38 states
(http://www.hcup-us.ahrq.gov/nisoverview.jsp#Data). An NIS-
implemented weighting strategy allows population-based esti-
mates to be drawn at the national level. Sampled hospitals are
assigned appropriate weights based on the number of hospitals
they represent in the database for a given year.8 Statistical analyses
were performed on weighted data and reported as weighted
frequencies.
Study population
The primary measured outcome for this study was in-hospital
mortality, defined as death prior to discharge regardless of cause
or time from operation. To identify all patient discharges with the
diagnosis of biliary tract cancer, diagnostic and procedural codes
were selected from the International Classification of Disease
Ninth Revision Clinical Modification (ICD-9 CM).9 The initial
cohort was limited to patients with malignant lesions of the biliary
tract; those undergoing resection of biliary tract cancers were then
identified based on ICD-9 procedure codes (Table 1).
Statistical analysis
All data were analysed using SAS version 9.1 (SAS Institute, Cary,
NC) advanced survey procedures. Univariate analyses of categori-
cal variables were performed using c2-tests, with P-values of <0.05
considered statistically significant. Trend analyses were performed
using the Mantel–Haenszelc2-test. Independent variables included
age group (<50, 50–59, 60–69,70), gender, race, admission status
(elective vs. emergent), diagnosis type (gall bladder cancer, intra-
hepatic ductal, extrahepatic ductal and contiguous sites), proce-
dure type (cholecystectomy, hepatic resection, duct resection and
pancreaticoduodenectomy), year of resection and hospital type
(teaching vs. non-teaching). Analyses also included medical
comorbidities from validated Elixhauser comorbidity software for
use with national datasets (congestive heart failure, diabetes mel-
litus, liver disease, obesity and peripheral vascular disease).10
The NIS classifies admission type into multiple categories,
including ‘emergency’, ‘urgent’ and ‘elective.’ For these analyses,
‘emergency’ and ‘urgent’ were combined into the variable ‘emer-
gent’ to provide a dichotomous comparison. Definitions of
admission type are derived from the UB-04, a universal billing
form developed by the American Hospital Association and insur-
ance industry to codify health care data collection; information
regarding this form is available through the Centers for Medicare
& Medicaid Services website (http://www.cms.hhs.gov/Manuals).
‘Emergency’ admission type is defined as one in which ‘the patient
required medical intervention as a result of severe, life-threatening
or potentially disabling conditions’. ‘Urgent’ admission type
requires ‘immediate attention for care and treatment of a physical
or mental disorder’. ‘Elective’ admission type permits ‘adequate
time to schedule the availability of a suitable accommodation’. 11
A multivariable logistic regression was assembled with
in-hospital mortality as the dependent variable. Unadjusted and
adjusted odds ratios were calculated to determine the effects of the
identified covariates on the outcome measure of in-hospital mor-
tality. Patient race was excluded from multivariate analysis sec-
ondary to prohibitive quantities of missing data. Logistic
regression was repeated after excluding cholecystectomy (open
and laparoscopic) as a covariate to address bias associated with the
likelihood that gall bladder cancers may frequently present and be
treated as acute cholecystitis. The adjusted odds ratios in this
subgroup were calculated to determine the independent effect of
admission type on in-hospital mortality.
Table 1 International Classification of Disease Ninth Revision Clinical Modification (ICD-9 CM) diagnostic and procedural codes
Diagnostic Code Diagnosis Procedural Code Procedure
156.0 Malignancy of the gallbladder 52.7 Pancreaticoduodenectomy, radical
155.1 Malignancy of intrahepatic bile ducts 51.63, 51.69 Bile duct resection (common bile duct or NOS)
156.1 Malignancy of extrahepatic bile ducts 51.21, 51.22 Open cholecystectomy
Laparoscopic cholecystectomy 51.23, 51.24
156.8 Malignancy of contiguous sites 50.22 Partial hepatectomy
230.8 Carcinoma in situ of the biliary system 50.3 Total hepatic lobectomy
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Results
Patient characteristics and univariate analyses are presented in
Tables 2 and 3, respectively. Predictors of in-hospital mortality
were examined using a multivariable logistic regression model
and are reported in Table 4. Results from the reconstructed mul-
tivariable logistic regression model excluding patients having
undergone laparoscopic or open cholecystectomy are presented in
Table 5.
Discussion
In the present study, the observed in-hospital mortality rate for all
patients undergoing resection for biliary tract cancers in NIS was
Table 2 Patient and hospital characteristics for all biliary tract cancer
resections, 1998–2006
Factor Total Weighted (%)
Total No. patients with Biliary
tract cancer
31 870 157 266
Resected patients 5 942 29 315 (18.6)
Age
Mean (median) 69.3 (70.0)
<50 479 2 366 (8.1)
50–59 832 4 117 (14.1)
60–69 1 363 6 749 (23.0)
70 3 264 16 063 (54.8)
Gender
Men 2 319 11 471 (39.1)
Women 3 623 17 824 (60.8)
Race
White 3 333 16 479 (73.7)
Black 374 1 819 (8.1)
Hispanic 507 2 451 (11.0)
Asian 173 857 (3.8)
Native American 24 120 (0.5)
Unknown 127 623 (2.8)
Comorbid Conditions
Congestive heart failure 2 281 11 270 (7.2)
Diabetes 5 499 27 093 (17.2)
Renal failure 855 4 170 (2.7)
Chronic lung disease 3 398 16 723 (10.6)
Peripheral vascular disease 751 3 709 (2.4)
Obesity 574 2 790 (1.8)
Type of Hospital
Teaching 3 247 16 312 (55.6)
Non-teaching 2 694 12 998 (44.2)
Admission Type
Emergency 2 628 12 929 (50.6)
Elective 2 551 12 640 (49.4)
Table 3 Univariate analysis of mortality (weighted): all resections
Factor n (%) P-value
Overall mortality 1638 (5.6) N/A
Gender 0.005
Men 763 (2.6)
Women 874 (3.0)
Age (years) <0.001
<50 19 (0.1)
50–59 131 (0.4)
60–69 323 (1.1)
70 1160 (4.0)
Year of procedure 0.527
1998 240 (0.8)
1999 167 (0.6)
2000 218 (0.7)
2001 176 (0.6)
2002 139 (0.5)
2003 193 (0.7)
2004 163 (0.6)
2005 156 (0.5)
2006 185 (0.6)
Diagnosis type 0.493
Gall bladder CA 876 (3.0)
Intrahepatic ductal CA 221 (0.8)
Extrahepatic ductal CA 375 (1.3)
Contiguous sites 166 (0.6)
Procedure type 0.104
Cholecystectomy 1042 (3.6)
Hepatic resection 281 (1.0)
Duct resection 92 (0.3)
Pancreaticoduodenectomy 223 (0.8)
Hospital type 0.072
Teaching 830 (2.8)
Non-teaching 807 (2.8)
Admission type* <0.001
Emergent 964 (3.6)
Elective 497 (1.9)
Comorbid conditions
Renal failure 181 (0.6) <0.001
Congestive heart failure 360 (1.2) <0.001
Peripheral vascular disease 58 (0.2) 0.036
Chronic lung disease 259 (0.9) 0.016
Diabetes 233 (0.8) 0.247
Obesity 23 (0.1) 0.050
CA, cancer.
*177 missing observations.
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5.6%. It was demonstrated that age greater than 50 and comor-
bidities such as congestive heart failure and renal failure were
independently associated with increased in-hospital mortality.
Finally, a significant mortality difference was discovered between
patients undergoing emergent resection procedures compared
with patients receiving elective procedures. After excluding all
cholecystectomies, for which definitions of emergent vs. elective
admission type may differ from major hepatobiliary operations,
the survival disadvantage of patients undergoing emergent proce-
dures persisted.
The role of elective vs. emergent operation for major operations
has been discussed in the context of other diseases. Poulose et al.
describe a six- to sevenfold adjusted increase in in-hospital mor-
tality associated with non-elective paraesophageal repair in a
population-based examination of octogenarians where nearly half
of the cohort underwent non-elective repairs.12 Khuri et al. also
identified ‘emergency status’ as one of five pre-operative variables
predictive of 30-day mortality in their analysis of eight major
operations performed in the Veterans Administration.13 McKay
et al. discuss ‘urgency of admission’ as a contributing predictor of
Table 4 Logistic regression of in-hospital mortality
Factor Odds ratio
(Unadjusted)
95% confidence
interval
Odds ratio
(Adjusted)
95% confidence
interval
Gender
Women (vs. men) 0.72 0.58–0.90 0.73 0.56–0.95
Age groups (years)
50–59 (vs. <50) 4.08 1.45–11.50 5.51 1.70–17.93
60–69 (vs. <50) 6.27 2.29–17.13 7.25 2.29–22.96
70 (vs. <50) 9.69 3.58–26.27 9.03 2.86–28.56
Diagnosis type
Intrahepatic ductal CA (vs. GBC) 1.24 0.88–1.75 1.42 0.97–2.09
Extrahepatic ductal CA (vs. GBC) 1.09 0.83–1.44 1.44 0.95–2.19
Contiguous sites (vs. GBC) 0.89 0.60–1.31 1.04 0.68–1.59
Procedure type
Cholecystectomy (vs. hepatectomy) 1.07 0.79–1.46 0.64 0.45–0.91
Duct resection (vs. hepatectomy) 0.79 0.47–1.32 0.60 0.33–1.10
PD (vs. hepatectomy) 1.18 0.79–1.76 0.84 0.50–1.42
Year of resection
1998 (vs. 2006) 1.06 0.68–1.65 1.31 0.81–2.14
1999 (vs.2006) 0.76 0.47–1.22 0.81 0.47–1.40
2000 (vs. 2006) 1.15 0.72–1.82 1.29 0.77–2.16
2001 (vs. 2006) 0.87 0.54–1.38 0.96 0.56–1.63
2002 (vs. 2006) 0.76 0.44–1.30 0.92 0.53–1.62
2003 (vs. 2006) 0.99 0.60–1.62 1.05 0.60–1.83
2004 (vs. 2006) 0.78 0.47–1.30 1.09 0.63–1.88
2005 (vs. 2006) 0.77 0.48–1.24 0.79 0.47–1.32
Comorbid conditions
Congestive heart failure 4.45 3.34–5.92 3.67 2.61–5.16
Renal failure 6.71 4.52–9.97 4.72 2.97–7.49
Peripheral vascular disease 1.91 1.04–3.52 1.18 0.56–2.49
Diabetes 0.83 0.60–1.14 0.72 0.50–1.03
Chronic lung disease 1.47 1.08–2.05 1.17 0.81–1.70
Obesity 0.42 0.17–1.03 0.51 0.19–1.39
Hospital type
Non-teaching (vs. teaching) 1.23 0.97–1.54 1.0 0.78–1.33
Admission type
Emergency (vs. elective) 1.87 1.47–2.38 1.82 1.39–2.37
GBC, gall bladder cancer; PD, pancreaticoduodenectomy.
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peri-operative mortality in their evaluation of surgeon training on
outcomes after hepatic surgery.14 The literature specific to biliary
tract cancer regarding the effect of admission type on mortality is,
however, sparse. Single institution data from multiple centres do
not examine admission status as a factor in their reviews of biliary
tract cancer mortality.15–21 Rather, evaluation of outcome in these
studies is focused on patient demographics, type of operation,
resection status and tumour grade. Of these characteristics, few
have the potential to correlate well with emergent admission;
jaundice, for instance, has been described as an adjusted risk
factor for poor outcome, but not in the context of emergent
admission.20,21
This analysis provides a current national view of surgical resec-
tion for biliary tract cancers, and provides the first US population-
based evidence that patients incur a significant increase in
mortality when undergoing emergent surgery for their biliary
tract cancers. Single-institutional experiences with biliary tract
cancers provide a wealth of data on a smaller number of patients,
being limited at most to a few hundred patients given that biliary
tract cancers are a rare disease. In contrast, this review of the NIS
data provides a significant cross-section of the US experience with
biliary tract cancers, enabling a robust analysis that supports
queries into subgroups of the original cohort. Although recently
published population-based investigations address intrahepatic
Table 5 Logistic regression of in-hospital mortality, cholecystectomy patients excluded
Factor Odds ratio (adjusted) 95% confidence interval
Gender
Women (vs. men) 0.59 0.36–0.95
Age groups (years)
50–59 (vs. <50) 3.43 1.02–11.48
60–69 (vs. <50) 5.31 1.63–17.31
>70 (vs. <50) 6.12 1.85–20.22
Diagnosis type
Intrahepatic ductal CA (vs. GBC) 3.45 1.70–7.02
Extrahepatic ductal CA (vs. GBC) 3.87 1.68–8.93
Contiguous sites (vs. GBC) 3.98 1.69–9.41
Procedure type
Duct resection (vs. hepatectomy) 0.43 0.21–0.88
PD (vs. hepatectomy) 0.59 0.31–1.11
Year of resection
1998 (vs. 2006) 0.76 0.35–1.62
1999 (vs.2006) 0.57 0.25–1.27
2000 (vs. 2006) 0.83 0.38–1.83
2001 (vs. 2006) 0.67 0.28–1.63
2002 (vs. 2006) 0.70 0.28–1.73
2003 (vs. 2006) 0.75 0.32–1.73
2004 (vs.2006) 0.66 0.30–1.49
2005 (vs.2006) 0.58 0.27–1.26
Comorbid conditions
Congestive heart failure 7.30 3.56–14.94
Renal failure 9.98 3.79–26.25
Peripheral vascular disease 0.54 0.09–3.17
Diabetes 0.37 0.15–0.92
Chronic lung disease 1.09 0.53–2.25
Hospital type
Non-teaching (vs. teaching) 1.26 0.80–1.99
Admission type
Emergency (vs. elective) 1.54 1.01–2.37
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cholangiocarcinoma, this study is the first to address in-hospital
mortality as an outcome for the larger group of all resected biliary
tract cancers.22,23
This study has several limitations. Administrative databases,
while broad in their nature, cannot provide relevant clinical detail
to the degree of that provided by single-institution databases or
clinician chart reviews; in particular, information such as tumour
size, staging and vascular invasion is unavailable in the NIS. The
NIS reports only in-patient mortality, preventing examination of
data pertaining to patients who were discharged, readmitted and
died subsequently in the hospital. Furthermore, additional end-
points other than hospital stay (e.g. 30-day and 60-day mortality)
are not available in the NIS, whereas they are used routinely in
Surveillance Epidemiology End Results (SEER)-based studies.23
Lastly, data that is longitudinal in nature, such as that pertaining
to pre- and post-hospital care, is excluded from the NIS, making
inquiries into referral and follow-up patterns impossible.
These results have several important implications for future
investigation. The finding of increased mortality for emergent
resection of biliary tract cancers may reflect the effects of a delay
in diagnosis, thus increasing morbidity and mortality for such
patients who do undergo resection. Future studies should be
directed at elucidating reasons for operating emergently, and at
examining safer alternatives for temporizing patients until elective
resection. In the case that emergent operation may not be avoided,
this data may have important ramifications for pre-operative
patient and family discussions. Ultimately, these results warrant
further investigation into the various means by which biliary tract
cancers could be detected and treated earlier.
In conclusion, this study queried a large nationally-
representative database to investigate in-hospital mortality for
resection for biliary tract cancer. Several factors were identified
that increased the odds of mortality, including congestive heart
failure, renal failure and emergent admission. These results
suggest that patients should be medically optimized prior to
surgery whenever possible. When this is not feasible, the mortality
risk this may confer should be discussed with patients.
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